Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Cell Therapeutics
So what: After shares jumped yesterday, shares have been crushed today after Cell Therapeutics announced that it has sold $21 million of preferred stock and warrants to institutional investors. This gives the company additional cash for operations but also dilutes current shareholders.
Now what: The preferred shares are convertible to common shares at $0.37 per share, so this should give investors some idea of the value big investors see in the shares. Investors also received warrants at $0.45 per share for up to 22.7 million shares. The price of this offering was much better than yesterday’s closing price of $0.44 per share and would make me rethink a long position in this speculative stock.
Interested in more info on Cell Therapeutics? Add it to your watchlist by clicking here.
